Joseph Catanzaro Analyst PerformanceAnalyst at Piper SandlerJoseph Catanzaro is a stock analyst at Piper Sandler focused in the medical sector, covering 29 publicly traded companies. Over the past year, Joseph Catanzaro has issued 38 stock ratings, including strong buy, buy, and hold recommendations. While full access to Joseph Catanzaro's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joseph Catanzaro's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings83 Last 7 YearsBuy Recommendations83.75% 67 Buy RatingsCompanies Covered29 Unique Companies Ratings Distribution80RatingsDistribution of strong buy, buy, hold, and sell ratings by Joseph Catanzaro.RatingPercentageCount Strong Buy10.0%8 ratings Buy73.8%59 ratings Hold16.3%13 ratings Sell0.0%0 ratingsOut of 80 total stock ratings issued by Joseph Catanzaro at Piper Sandler, the majority (73.8%) have been Buy recommendations, followed by 16.3% Hold and 10.0% Strong Buy.Best & Worst CallsBest Call0000.0%CTMXApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%FIGSAug 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.6% of companies on NASDAQ28 companiesNYSE3.4% of companies on NYSE1 companyJoseph Catanzaro, an analyst at Piper Sandler, currently covers 29 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical27 companies93.1%Manufacturing1 company3.4%Retail/Wholesale1 company3.4%Joseph Catanzaro of Piper Sandler specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and Retail/Wholesale companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE21 companies72.4%MED - DRUGS3 companies10.3%BIOTECHNOLOGY2 companies6.9%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company3.4%MEDICAL INFO SYS1 company3.4%RETAIL - APP/SHOE1 company3.4% Joseph Catanzaro's Ratings History at Piper Sandler Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsAVTXAvalo Therapeutics5/14/2026Boost Price Target$19.85$45.00Outperform$0.0000.00% ROIUPBUpstream Bio5/14/2026Lower Price Target$9.36$50.00Outperform$0.0000.00% ROIERASErasca5/12/2026Lower Price Target$10.44$26.00Outperform$0.0000.00% ROICLYMClimb Bio4/15/2026Initiated Coverage$8.85$18.00Outperform$0.0000.00% ROICLYMClimb Bio4/15/2026Initiated Coverage$8.65$18.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics3/30/2026Boost Price Target$78.10$110.00Outperform$0.0000.00% ROICTMXCytomX Therapeutics3/23/2026Boost Price Target$4.47$12.00Overweight$0.0000.00% ROIERASErasca3/13/2026Boost Price Target$15.19$19.00Outperform$0.0000.00% ROITNGXTango Therapeutics3/11/2026Boost Price Target$16.34$20.00Outperform$0.0000.00% ROIIBRXImmunityBio3/4/2026Reiterated Rating$10.00$12.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. EIKNEIKN3/2/2026Initiated Coverage$13.78$26.00Outperform$0.0000.00% ROITNGXTango Therapeutics2/23/2026Initiated Coverage$12.20$19.00Outperform$0.0000.00% ROINRIXNurix Therapeutics1/29/2026Boost Price Target$17.87$35.00Overweight$0.0000.00% ROIIBRXImmunityBio1/20/2026Boost Price Target$5.52$7.00Overweight$0.0000.00% ROICTMXCytomX Therapeutics1/20/2026Boost Price Target$5.39$10.00Overweight$0.0000.00% ROIAVTXAvalo Therapeutics12/18/2025Upgrade$18.91Strong-Buy$0.0000.00% ROIBCAXBicara Therapeutics12/18/2025Upgrade$17.64Hold$0.0000.00% ROISYRESpyre Therapeutics12/18/2025Upgrade$33.47Strong-Buy$0.0000.00% ROIUPBUpstream Bio12/18/2025Upgrade$29.86Strong-Buy$0.0000.00% ROIAVTXAvalo Therapeutics12/17/2025Set Price Target$19.25$39.00Outperform$0.0000.00% ROIUPBUpstream Bio12/17/2025Initiated Coverage$28.33$51.00Outperform$0.0000.00% ROIBCAXBicara Therapeutics12/17/2025Initiated Coverage$17.98$18.00Neutral$0.0000.00% ROISYRESpyre Therapeutics12/17/2025Initiated Coverage$33.06$53.00Outperform$0.0000.00% ROIKYMRKymera Therapeutics12/11/2025Boost Price Target$89.89$120.00Outperform$0.0000.00% ROINRIXNurix Therapeutics12/10/2025Boost Price Target$19.87$30.00Outperform$0.0000.00% ROIRVMDRevolution Medicines10/21/2025Initiated Coverage$54.01$90.00Outperform$0.0000.00% ROINRIXNurix Therapeutics10/21/2025Initiated Coverage$10.39$24.00Outperform$0.0000.00% ROIKYMRKymera Therapeutics10/21/2025Initiated Coverage$60.50$81.00Outperform$0.0000.00% ROICLDXCelldex Therapeutics10/21/2025Initiated Coverage$27.67$48.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics10/21/2025Initiated Coverage$56.94$105.00Outperform$0.0000.00% ROIAPGEApogee Therapeutics10/20/2025Upgrade$53.48Strong-Buy$0.0000.00% ROICLDXCelldex Therapeutics10/20/2025Upgrade$26.72Strong-Buy$0.0000.00% ROIKYMRKymera Therapeutics10/20/2025Upgrade$55.80Strong-Buy$0.0000.00% ROINRIXNurix Therapeutics10/20/2025Upgrade$10.63Strong-Buy$0.0000.00% ROIRVMDRevolution Medicines10/20/2025Upgrade$52.98Strong-Buy$0.0000.00% ROINRIXNurix Therapeutics10/10/2025Lower Price Target$10.86$32.00Overweight$0.0000.00% ROIIBRXImmunityBio5/20/2025Upgrade$2.80$5.00Overweight$0.0000.00% ROICTMXCytomX Therapeutics5/15/2025Boost Price Target$1.99$5.00Overweight$0.0000.00% ROICTMXCytomX Therapeutics4/14/2025Initiated Coverage$0.53$2.50Overweight$0.0000.00% ROIIOVAIovance Biotherapeutics2/28/2025Lower Price Target$5.26$6.00Neutral$0.0000.00% ROIBefore you buy SpaceX shares, consider this alternative approach (Ad)SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.Discover the overlooked SpaceX IPO strategy before the June listingSDGRSchrodinger2/27/2025Lower Price Target$21.70$45.00Overweight$00.0000.00% ROIMRUSMerus2/13/2025Initiated Coverage$40.26$84.00Overweight$0.0000.00% ROIGILDGilead Sciences2/12/2025Boost Price Target$103.45$110.00Overweight$000.0000.00% ROIEXELExelixis2/12/2025Boost Price Target$34.91$38.00Overweight$00.0000.00% ROIIOVAIovance Biotherapeutics1/31/2025Lower Price Target$6.01$7.50Neutral$0.0000.00% ROIKROSKeros Therapeutics1/17/2025Lower Price Target$11.09$15.00Overweight$00.0000.00% ROIEXELExelixis1/13/2025Boost Price Target$35.09$37.00Overweight$00.0000.00% ROIHALOHalozyme Therapeutics1/10/2025Boost Price Target$53.13$53.00Neutral$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageMorgan StanleyJefferies Financial GroupStifel NicolausOppenheimerBerenberg BankRoth MkmWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD Cowen Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
